Highlights

  • AML3D received an approximately AUD 2.2 million ARCEMY X order in October.
  • The order includes a two-year maintenance and services package.
  • AML3D (ASX:AL3) reported FY26 Revenue including leases of AUD 12.5 million.
  • Contracted work carried into FY27 amounted to AUD 16.8 million.

AML3D Limited designs industrial metal-additive-manufacturing systems and supplies manufactured parts for defence and other industrial applications. AML3D (ASX:AL3) shares were quoted at AUD 0.10 on November 19, 2026, with a daily change of 0.00%. Its latest commercial developments include an October ARCEMY system order, following FY26 revenue growth and expanding contracted work.

Northrop Grumman Contract and Delivery Terms

AML3D announced an approximately AUD 2.2 million initial order for an ARCEMY X metal-additive-manufacturing system from Northrop Grumman Marine Systems on October 26, 2026. The order followed a competitive tender and includes two years of maintenance and services. The system is to be supplied from the company’s Stow, Ohio Facility and installed in Sunnyvale, California. Under the disclosed terms, 50% of the amount is payable after an initial project milestone, with later milestone payments through final installation, expected in the fourth quarter of FY27.

US Defence Manufacturing Footprint

The company said the new order brought its US contracts to 17 ARCEMY systems, across customers that include defence-industry manufacturers. Its strategy involves supplying industrial-scale metal printing equipment and manufacturing components for maritime and other applications. Defence procurement can involve technical qualification, installation milestones and customer acceptance before an order translates fully into cash. Accordingly, the headline value of the October contract should not be equated with revenue recognised immediately in the quarter.

FY26 Results and Contracted Work

For the year ended June 30, 2026, AML3D reported AUD 12.5 million of revenue including Lease income, representing 70% year-on-year growth. It also reported second-half EBITDA of AUD 608,000 and AUD 26.7 million of cash at year-end. Confirmed work rolling into FY27 was AUD 16.8 million, compared with AUD 9 million carried into the previous year. These disclosures provide a financial context for the subsequent Northrop Grumman order, although contract backlogs and future sales pipelines are not the same as completed sales.

Manufacturing Capacity and Previous Orders

During 2026 the company also reported commissioning two custom ARCEMY X systems for Newport News Shipbuilding, completing an initial order valued at approximately AUD 4.5 million. A separate order for four further systems carried an approximate AUD 9.9 million value, with delivery targeted for early 2027. These orders indicate a continuing equipment-delivery schedule alongside component production work. The commercial significance depends on meeting technical requirements, installation schedules and customer acceptance, all of which can affect the timing of recognition and payment.

Execution Risks in Advanced Manufacturing

Large industrial additive-manufacturing projects face risks relating to specialist components, testing, Supply chains and customer-specific qualification. The Northrop Grumman contract calls for delivery to a defined facility, and other contracts have their own milestones. A rising Backlog increases the importance of engineering capacity and working-capital discipline while projects are being delivered.

What to Watch in FY27

Relevant upcoming events include installation of the Northrop Grumman equipment, delivery of the additional Newport News Shipbuilding systems and reporting on conversion of carried-forward contracts into revenue. Investors can also monitor the balance between system sales, parts manufacturing and recurring maintenance income. The company’s FY26 sales-pipeline estimate represented possible future work, not committed orders, so later disclosures should clearly distinguish bids, awarded contracts, installed systems and recognised revenue.

Key Insights

AML3D entered FY27 with a larger contracted workload and reported an additional ARCEMY X order in October 2026. The company’s FY26 revenue increased while its second-half EBITDA turned positive, based on its disclosed measures. The operational focus is now on installation, delivery schedules and collection of milestone payments. These concrete execution indicators provide a more reliable basis for assessing the unfolding contract programme than assuming all announced contract values will be recognised at once.